Share Your Voice

Tell the FDA Why New Treatment Options Matter

The FDA’s decision to decline approval for a promising new treatment for advanced melanoma—vusolimogene oderparepvec (RP1) combined with nivolumab (Opdivo)—will affect many patients.

AIM at Melanoma wants to help share the voices of patients and families who are most impacted by this decision—and anyone who wants to express an opinion about the importance of approving new treatments.

Please help the FDA understand the real-life experiences of those living with melanoma.

How You Can Help

Real lives are affected when effective drugs are denied approval. There are many people who could benefit from this treatment; there are many lives that might be saved. Sharing your story can help the FDA better understand what these decisions mean to real patients.

Here are some suggested talking points

• Patients need more treatment options. People with advanced melanoma who do not respond or stop responding to current therapies—like anti–PD-1 drugs—have very few choices left
• Many communities lack access to a viable treatment option as they do not live near a major cancer center
• What do you want the FDA to understand about living with melanoma?
• How do you feel about the FDA’s decision?
• Your experience in the RP1/nivolumab trial, or any clinical trial
• What would access to more treatment options mean (or what would access have meant) to you or your loved one?
• What has your treatment journey been like?

Share Your Thoughts

When completing the form below, it is okay to use some kind of general identifier such as “Jennifer P., Oregon” or “Stage IV patient, Minnesota”. You can also leave the name field blank and be anonymous.